Elobixibat Completed Phase 2 Trials for Nonalcoholic Fatty Liver / Non Alcoholic Steatohepatitis (NASH) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04235205Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease